Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Equity Offering 16
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC – Key Competitors 21
Deciphera Pharmaceuticals LLC – Key Employees 22
Deciphera Pharmaceuticals LLC – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Deciphera Pharmaceuticals announces second quarter 2018 financial results 24
May 08, 2018: Deciphera Pharmaceuticals Announces First Quarter 2018 Financial Results 26
Mar 28, 2018: Deciphera Pharmaceuticals Announces Fourth Quarter 2017 Financial Results and Corporate Highlights 27
Nov 14, 2017: Deciphera Pharmaceuticals Announces Third Quarter 2017 Financial Results and Corporate Highlights 29
Corporate Communications 30
May 29, 2018: Deciphera Pharmaceuticals Names Stephen B. Ruddy As Chief Technical Officer 30
May 21, 2018: Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director 31
Product News 32
11/06/2017: Deciphera Pharmaceuticals to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 32
Product Approvals 33
Nov 28, 2017: Deciphera Pharmaceuticals Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors 33
Sep 05, 2017: Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma 34
Clinical Trials 35
Jan 04, 2018: Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS study”) 35
Nov 20, 2017: Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 36
Nov 10, 2017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society 37
Sep 11, 2017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress 38
Aug 31, 2017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress 39
Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting 40
May 18, 2017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting 41
Apr 03, 2017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC, Key Competitors 21
Deciphera Pharmaceuticals LLC, Key Employees 22
Deciphera Pharmaceuticals LLC, Other Locations 23
List of Figures
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9